Rui‐Hua Xu
Rui‐Hua Xu publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Molecular Biology, on topics such as Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies and Cancer Immunotherapy and Biomarkers.
- World rank
- #75,263 of 7,710,434 ranked researchers
- Rank in China
- #6,092 of 978,568
- Works
- 1,463
- Citations
- 57k
- Citations per work
- 38.7
What does Rui‐Hua Xu research?
Rui‐Hua Xu's work is mostly in Medicine (44%), Biochemistry, Genetics and Molecular Biology (18%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences64143.8%
- Medicine64143.8%
- Everything else55437.9%
- Life Sciences26818.3%
- 1Oncology21% of their works
- 2Pulmonary and Respiratory Medicine12% of their works
- 3Molecular Biology12% of their works
- 4Surgery7% of their works
- 5Cancer Research7% of their works
- 6Pathology and Forensic Medicine4% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
Which keywords describe Rui‐Hua Xu's research?
The keywords of their largest research topics: Chemotherapy, Endoscopic Resection, Gastric Cancer, Molecular Characterization, Cetuximab, KRAS Mutations, Targeted Therapy and Epidemiology.
- Cholangiocarcinoma
- Sunitinib
- Imatinib Mesylate
- Preoperative Chemoradiotherapy
- EGFR Mutations
- PD-1 and PD-L1
- Surgical Management
- Epidemiology
- KRAS Mutations
- Molecular Characterization
- Endoscopic Resection
- Chemotherapy
- Gastric Cancer
- Cetuximab
- Targeted Therapy
- Prognostic Factors
- Immune Checkpoint Blockade
- ALK Inhibitors
- Esophageal Carcinoma
- Cancer Genomics
- Mutational Signatures
- Biliary Tract Cancer
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Chemotherapy4432 topics
- Endoscopic Resection2972 topics
- Gastric Cancer2241 topic
- Molecular Characterization2241 topic
- Cetuximab2191 topic
- KRAS Mutations2191 topic
- Targeted Therapy1372 topics
- Epidemiology1322 topics
- Prognostic Factors1232 topics
- Surgical Management1232 topics
- Immune Checkpoint Blockade1071 topic
- PD-1 and PD-L11071 topic
- ALK Inhibitors731 topic
- EGFR Mutations731 topic
- Esophageal Carcinoma731 topic
- Preoperative Chemoradiotherapy731 topic
- Cancer Genomics641 topic
- Imatinib Mesylate641 topic
- Mutational Signatures641 topic
- Sunitinib641 topic
- Biliary Tract Cancer591 topic
- Cholangiocarcinoma591 topic
Where does Rui‐Hua Xu work?
Rui‐Hua Xu's main affiliation in the publication record is Sun Yat-sen University, China.
How many publications and citations does Rui‐Hua Xu have?
OpenAlex counts 1,463 works and 56,636 citations for Rui‐Hua Xu, an h-index of 105, ranking #75,263 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Rui‐Hua Xu. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.